Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (Nasdaq: GILD) today ...
Merck has rebounded 55% in the past year, driven by optimism around its post-Keytruda strategy despite the looming patent ...
Merck & Co., Inc. (NYSE:MRK) is one of the best cheap stocks to buy for beginners. Moderna, Inc. and Merck & Co., Inc.
Investors have bet new drugs can topple Merck’s Keytruda, but the evidence so far points to something smaller.
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in ...
After ICIJ’s The Cancer Calculus investigation exposed a market for falsified Keytruda, two sources confirmed Friday that ...
Moderna and Merck present 5-year data for intismeran autogene in combo with Keytruda in patients with high-risk stage III/IV melanoma following complete resection at 2026 ASCO mee ...
TheFly reported on May 22 that MRK announced that the European Medicines Agency’s Committee for Medicinal Products for Human ...
More biopharma layoffs are hitting New Jersey, this time from Merck & Co.in the latest phase of headcount reductions ...
Merck & Co.’s extensive clinical development scheme for its TROP2 antibody-drug conjugate (ADC) sac-TMT already ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results